1型糖尿病(若年性糖尿病)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0647
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:684
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2019, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 3, 11, 35, 23, 1, 115, 23 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 2, 1, 30 and 4 molecules, respectively.

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Type 1 Diabetes (Juvenile Diabetes) – Overview
Type 1 Diabetes (Juvenile Diabetes) – Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) – Therapeutics Assessment
Type 1 Diabetes (Juvenile Diabetes) – Companies Involved in Therapeutics Development
Type 1 Diabetes (Juvenile Diabetes) – Drug Profiles
Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects
Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products
Type 1 Diabetes (Juvenile Diabetes) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H2 2019
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H2 2019

【掲載企業】

Adocia SAS
Aerami Therapeutics
Ahead Therapeutics SL
Akston Biosciences Corp
Algiax Pharmaceuticals GmbH
Allist Shanghai Pharmaceutical Technology Co Ltd
Altheia Science SRL
ALTuCELL
Amarantus Bioscience Holdings Inc
Amarna Therapeutics BV
AmideBio LLC
Anokion SA
apceth Biopharma GmbH
Aphios Corp
Apodemus AB
APT Therapeutics Inc
Aptamer Sciences Inc
Arecor Ltd
Ariddad Therapeutics SL
Artery Therapeutics Inc
AstraZeneca Plc
Atlantic Bio Sci LLC
Auxulin Pharmaceuticals Inc
AVM Biotechnology LLC
Avotres Inc
Axxam SpA
Beta-Cell NV
Biocon Ltd
BioLineRx Ltd
BioLingus AG
Bioorg3.14 LLC
Biozeus Pharmaceutical SA
BirchBioMed Inc
Boehringer Ingelheim International GmbH
Bol Pharma
Boston Therapeutics Inc
Bristol-Myers Squibb Co
BTB Pharma AB
Cancer Prevention Pharmaceuticals Inc
CAR-T (Shanghai) Biotechnology Co Ltd
Carlina Technologies SAS
CellTrans Inc
Chongqing Chenan BioPharm Co Ltd
Compugen Ltd
Cour Pharmaceuticals Development Co Inc
CRISPR Therapeutics AG
Cyteir Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Denceptor Therapeutics Ltd
Dendright Pty Ltd
Diabetology (Products) Ltd
Diamyd Medical AB
Diasome Pharmaceuticals Inc
DiaVacs Inc
Dompe Farmaceutici SpA
Dualogics Corp
Eli Lilly and Co
Endsulin LLC
Ensol Biosciences Inc
Enthera Srl
EpiVax Inc
Evotec SE
Fairbanks Pharmaceuticals Inc
FasCure Therapeutics LLC
Follicum AB
Gan & Lee Pharmaceutical Ltd
Generex Biotechnology Corp
GeNeuro SA
Geropharm
Gubra ApS
Hanmi Pharmaceuticals Co Ltd
Housey Pharmaceutical Research Laboratories LLC
Iltoo Pharma
ImCyse SA
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Innovimmune Biotherapeutics Inc
Intrexon Corp
Inversago Pharma Inc
Islexa Ltd
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
Jortan Pharmaceuticals Inc
Kadimastem Ltd
Kamada Ltd
Kunming Yinnuo Medical Technology Co. Ltd.
L2 Diagnostics LLC
Landos Biopharma Inc
Larix Bioscience LLC
Lexicon Pharmaceuticals Inc
MannKind Corp
Maruho Co Ltd
Medytox Inc
Mercia Pharma Inc
Merck & Co Inc
Metavant Sciences Ltd
MidaSol Therapeutics LP
Neovacs SA
NextCell Pharma AB
Novartis AG
Novo Nordisk AS
OneVax LLC
Op-T-Mune Inc
Oramed Pharmaceuticals Inc
Orgenesis Inc
Orion BioScience Inc
OSE Immunotherapeutics
Pancryos
Pandion Therapeutics Inc
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
Pfizer Inc
PharmaCyte Biotech Inc
PharmaIN Corp
PolTREG Sp z o o
Polus Inc
Prometheon Pharma LLC
Protomer Technologies Inc
Provention Bio Inc
Purzer Pharmaceutical Co Ltd
Radikal Therapeutics Inc
RedHill Biopharma Ltd
REGiMMUNE Corp
Reliance Life Sciences Pvt Ltd
Remd Biotherapeutics Inc
reMYND NV
Renova Therapeutics Inc
Rezolute Inc
Rubius Therapeutics Inc
SAB Biotherapeutics Inc
Sahane Biotech Inc
Sanofi
Semma Therapeutics Inc
Sensulin LLC
Seraxis Inc
Serpin Pharma LLC
Sihuan Pharmaceutical Holdings Group Ltd
Sotio AS
SQZ Biotechnologies Co
Suntec Medical (Taiwan) Inc
SymbioCellTech LLC
Tetragenetics Inc
Thermalin Diabetes LLC
Toleranzia AB
Tolerion Inc
Tolerx, Inc. (Inactive)
Topas Therapeutics GmbH
Transgene Biotek Ltd
Unicyte AG
Valin Technologies Ltd
Ventria Bioscience
Veralox Therapeutics Inc
ViaCyte Inc
ViCapsys Inc
Virtici LLC
vTv Therapeutics Inc
XERIS Pharmaceuticals Inc
XL-protein GmbH
Yichang Hec Changjiang Pharmaceutical Co Ltd
Youngene Therapeutics Co Ltd
Zealand Pharma AS
Zhejiang Hisun Pharmaceutical Co Ltd


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[1型糖尿病(若年性糖尿病)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆